At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 17, 2026 at 17:33 ET
Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its remaining biosimilar assets, completing its transformation into a pure-play immuno-oncology company. The CVRs entitle holders to a pro rata share of net proceeds from the sale of patents, IP, royalties, and cell lines, but payments are uncertain and subject to a 2026 loan agreement. The CVRs expire on October 7, 2028, with no guaranteed payout, making this a speculative unlock of non-core asset value.
- Coherus declared a special dividend of CVRs to stockholders of record as of September 30, 2026, with a distribution date of October 7, 2026.
- CVRs entitle holders to net cash proceeds from the sale of Legacy BioSim Assets, including patents, IP, royalties, cell lines, and related materials.
- The CVRs are non-transferable, will not be listed on any exchange, and expire on October 7, 2028, with no payment if no proceeds are received.
- The company has retained an investment bank to assist in the sale process and is subject to restrictions under a Loan Agreement with Innovatus Life Sciences Lending Fund I, L.P., dated August 12, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access